Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.
[More]
Breast cancer survivors are among the women who could most benefit from regular physical activity, yet few meet national exercise recommendations during the 10 years after being diagnosed, according to a study by researchers at Fred Hutchinson Cancer Research Center.
[More]
More than 50 million Americans suffer from allergies and asthma, a number that continues to rise annually. To help children and adults with symptoms of these conditions know if they are at risk, allergists from around the country will conduct the 17th annual Nationwide Asthma Screening Program.
[More]
The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.
[More]
A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.
[More]
Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are a promising approach to treat cancer with the aim to selectively reactivate the body's own immune system so that it attacks tumor cells.
[More]
More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.
[More]
Although previous research has linked alcohol consumption to an increased risk of developing breast cancer, a new study has found that drinking before and after diagnosis does not impact survival from the disease.
[More]
The recent discovery of circulating "nano-sized extracellular vesicles" (EVs) carrying proteins and nucleic acids derived from brain tumors may lead to exciting new avenues for brain cancer diagnosis, monitoring, and treatment, according to a special article in the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
[More]
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.
[More]
Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).
[More]
Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.
[More]
NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.
[More]
Nektar Therapeutics today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research Annual Meeting.
[More]
A physician-researcher from The Children's Hospital of Philadelphia will lead the first-ever pediatric "Dream Team" solely focused on creating new treatments for the most challenging childhood cancers.
[More]
As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today in a press conference at the AACR Annual Meeting 2013 (Presentation #LB-335).
[More]
Harnessing the patient's own immune system to fight cancer through genetic modification of their own cells is rapidly emerging as a promising treatment option.
[More]
Treating patients with cells may one day become as common as it is now to treat the sick with drugs made from engineered proteins, antibodies or smaller chemicals, according to UC San Francisco researchers.
[More]
Recently, research using adoptive T-cell immunotherapy in blood cancers have shown success, most notably in the case of a seven-year-old girl whose leukemia went into remission using altered T-cells and a disabled HIV virus.
[More]
Asthma is becoming an epidemic in the United States. The number of Americans diagnosed with asthma grows annually, with 26 million currently affected. And according to a new study, nearly two-thirds or more of all asthmatics also have an allergy, which can make this spring season particularly bothersome.
[More]